Phage Therapy Investigated for Cystic Fibrosis
Enrollment has begun in an early-stage clinical trial evaluating phage therapy (bacteriophage) in adults with cystic fibrosis who carry Pseudomonas aeruginosa in their lungs.
Category: Clinical Trials
Clinical Trials
Latest
Clinical Trials
Latest
Albuterol + Budesonide Cut Risk of Asthma Exacerbation by 27%
Two combinations of albuterol and budesonide used as a rescue medication demonstrated a statistically significant reduction in the risk of a severe exacerbation in patients with moderate to severe asthma.
Clinical Trials
Latest
Regen-Cov Reduced COVID Risk for up to Eight Months
A single dose of Regeneron Pharma's antibody cocktail casirivimab and imdevimab (trade name Regen-Cov) reduced the risk of COVID-19 by 81.6% for up to eight months, according to a Phase 3 trial.
NIH to Study Antibody Responses in Vaccinated Pregnant Women and Their Infants
The NIH has begun evaluating the immune responses generated by COVID-19 vaccines administered to pregnant or postpartum women and their infants.
Read More
Novavax COVID-19 Vaccine 90% Effective Overall in Ph3 Trial
Novavax Inc’s COVID-19 vaccine NVX-CoV2373 demonstrated 90.4% overall efficacy against SARS-CoV-2 infection, and 100% protection against moderate and severe disease, according to a Phase 3 PREVENT-19 clinical trial.
Read More
NIH Begins Research into Mixed COVID-19 Booster Vaccines
An NIH Phase 1/2 clinical trial will study fully-vaccinated adult volunteers who will receive booster doses of different COVID-19 vaccines to determine the safety and immunogenicity of mixed boosted regimens.
Read More
Dupilumab Significantly Reduced Asthma Exacerbations in Children Ages 6-11
A clinical trial of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo.
Read More
Long-term Data Shows Safety, Effectiveness of Fasenra for Severe Eosinophilic Asthma
A five-year trial found at least 75% of Fasenra-treated asthma patients with elevated blood eosinophil levels had zero exacerbations each year of the open-label period.
Read More
Tezepelumab Reduced Exacerbation Rates in severe Asthma 77%
A Phase 3 trial of AstraZeneca/Amgen’s Tezepelumab found the drug had a clinically meaningful 77% reduction in annualized asthma exacerbation rates in patients with severe asthma.
Read More
Trial to Test Dalbavancin as Treatment for S. aureus
NIH will conduct a clinical trial to test the antibiotic dalbavancin for safety and efficacy in treating complicated Staphylococcus aureus (S. aureus) bacteremia.
Read More
Clinical Trial Begins for 2nd-Gen COVID-19 Vaccine
A Phase I/II clinical trial in the Netherlands will test AKS-452, a COVID-19 vaccine candidate that is shelf-stable for at least 4 months without refrigeration.
Read More
NIH to Trial Repurposed Drugs for COVID-19
A Phase 3 clinical trial will explore a pool of up to seven drugs approved by FDA for other conditions – an approach called drug repurposing – and test their safety and effectiveness in treating mild to moderate COVID-19.
Read More
Experimental Antiviral MK-4482 Effective for SARS-CoV-2
The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from National Institutes of Health scientists.
Read More
Regeneron Monoclonal Antibodies Reduced COVID-19 Transmission Risk by 81%
Regen-CoV — a monoclonal antibody cocktail from Regeneron — reduced the risk of symptomatic SARS-CoV-2 infections by 81% in a Phase 3 clinical trial.
Read More
Six Months of Data Show 91.3% Efficacy for Pfizer Vaccine in Adults
Updated Phase 3 data analyzing the Pfizer-BioNTech COVID-19 vaccine up to six months after second vaccination showed it was 91.3% effective overall and 100% effective versus severe disease.
Read More